Drug Profile
Modimelanotide
Alternative Names: ABT-719; AP-214; ZP-1480Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Action Pharma
- Developer AbbVie; Action Pharma
- Class Anti-inflammatories; Melanocyte-stimulating hormones; Peptides; Small molecules
- Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute kidney injury; Adult respiratory distress syndrome; Multiple organ failure; Myocardial infarction; Reperfusion injury
Most Recent Events
- 19 Sep 2014 Discontinued - Phase-II for Acute kidney injury (Prevention) in Denmark (IV)
- 19 Sep 2014 Discontinued - Phase-II for Acute kidney injury (Prevention) in USA (IV)
- 01 Jun 2014 AbbVie terminates a phase II trial for Acute kidney injury (prevention) in USA and Denmark (NCT01897519)